2026 Columbus Patient and Family Conference
Saturday, October 24, 2026
Conference Co-Chairs
Uma Borate, MBBS
Alice Mims, MD
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Xiaoyi Chen, MD, PhD
Institution
Rutgers Cancer Institute of New Jersey
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Chen is currently with the Rutgers Cancer Institute, the only NCI-designated cancer center in the state, where cutting-edge cancer research is conducted and state-of-the-art cancer care is delivered. Her interest in hematological malignancies started in medical school, driving her to pursue research in this field. After graduating from West China Medical School, she joined the University of Cincinnati’s Cancer and Cell Biology program, where her primary research focused on targeting autophagy in acute leukemia and earned my PhD. Following this, she completed her internal medicine residency
Prophylaxis and management of thromboembolism in pnh patients: an italian survey
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria:
Fueling Your Journey: Nutrition Support for Aplastic Anemia, MDS, and PNH
Topic(s)
Aplastic Anemia
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this webinar, Sondos Khattab, Registered Dietitian, will discuss practical tips for managing treatment-related challenges, food safety, and making informed nutrition choices to support overall health. Questions can be submitted in advance at help@aamds.org.
What is my diagnosis? From the 2026 AAMDSIF Patient and Family Conference
Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Bart Scott, MD
Dr. Bart Scott provides an overview of aplastic anemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and paroxysmal nocturnal hemoglobinuria (PNH). He explains the diagnostic tests and criteria used to make an accurate diagnosis.
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Original Publication Date
Article Source
External Web Content
Summary Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and…
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry
Ravulizumab, a second-generation complement component 5 inhibitor (C5i) derived from eculizumab eculizumab: